Source: Annual Congress 2002 - Pulmonary pot pourri
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. S. Papakosta, J. Goutsikas, T. Kontakiotis, L. Sichletidis, D. Gioulekas, D. Patakas (Thessaloniki, Greece). Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF. Eur Respir J 2002; 20: Suppl. 38, 2834

Member's Comments

No comment yet.

Related content which might interest you: Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Peculiarities of pulmonary alveolar proteinosis (PAP) due to exogenous factors Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease Year: 2020 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Pulmonary alveolar proteinosis: from classification to therapy Source: Breathe, 16 (2) 200018; 10.1183/20734735.0018-2020 Year: 2020 Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Pulmonary alveolar proteinosis Source: Eur Respir Rev 2011; 20: 98-107 Year: 2011 Pulmonary alveolar proteinosis Source: Eur Respir Mon; 2009: 46: 208–224 Year: 2009 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Efficacy of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) in a Japanese female patient with pulmonary alveolar proteinosis (PAP) Source: Eur Respir J 2001; 18: Suppl. 33, 221s Year: 2001 Our cases with pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Plasmapheresis for treatment of pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1220-1222 Year: 2009 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015